Table search / Metagenomi, Inc. Common Stock / "Healthcare"

From 2020 to 2021, we sold an aggregate of 9,861,297 Series A-4 and Series A-5 preferred units in multiple closings, consisting of (i) 8,280,360 Series A-4 preferred units sold at a purchase price of $4.84875 per unit for an aggregate amount of $40.1 million and (ii) 1,580,937 Series A-5 preferred units sold at a purchase price of $6.32536 per unit for an aggregate amount of $10.0 million, for total aggregate proceeds of $50.1 million. The following table summarizes purchases of our Series A-4 and Series A-5 preferred units as described above by related persons:

We have determined beneficial ownership in accordance with the rules of the SEC, and the information is not necessarily indicative of beneficial ownership for any other purpose. These rules generally attribute beneficial ownership of securities to persons who possess sole or shared voting power or investment power with respect to those securities as well as any shares of common stock that the person has the right to acquire within 60 days of January 24, 2024 through the exercise of stock options or other rights. These shares are deemed to be outstanding and beneficially owned by the person holding those options for the purpose of computing the percentage ownership of that person, but they are not treated as outstanding for the purpose of computing the percentage ownership of any other person. Unless otherwise indicated, the persons or entities identified in this table have sole voting and investment power with respect to all shares shown as beneficially owned by them.

In 2022 and 2023, we sold an aggregate of 22,162,743 Series B and Series B-1 preferred units in multiple closings, consisting of (i) 15,054,263 Series B preferred units, which includes (a) 12,446,876 Series B preferred units sold at a purchase price of $11.64951 per unit and (b) 2,607,387 Series B preferred units which converted pursuant to a promissory note with a principal amount of $30.0 million and accrued interest of $0.4 million between the Company and ModernaTx, Inc., for an aggregate amount of $175.4 million and (ii) 7,108,480 Series B-1 preferred units sold at a purchase price of $14.06770 per unit for an aggregate amount of $100.0 million, for total aggregate proceeds of $275.4 million. The following table summarizes purchases of our Series B and Series B-1 preferred units by related persons: